arrow_back Back Filing freshness 10-Q Q3 FY2026 SEC EDGAR

BIOVIE INC.

BIVI
$1.02 ▼ -0.33 (-24.72%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
53 Visible periods
23 Metrics
Peer-ranked Benchmarks
Price Chart
23
Health
Poor
Bearish
auto_awesome

Analytical Summary

BIOVIE INC. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $7.7M
Dividend Yield
Revenue Growth
Op. Margin
ROIC -27.3%
FCF / Share $-0.99
Trailing P/E
Price / Book 0.5x
FCF Yield
Debt / Equity
info Valuation on last close. End-of-day price, Aug 7, 2026.

53-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Net Income Profit after all expenses
$-5.09M
↓ -22.5%
FCF / Share Free cash flow per share
$-0.99
↓ -76.1%
Long-Term Debt Long-term obligations
$62.50K
— 0.0%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns
10
Financial Health
16
Cash Quality
69

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 13 years · 53 quarters